Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QN-302 in Advanced Solid Tumors
NCT06086522Phase 1Recruiting
- Sponsor
- Qualigen Therapeutics, Inc.
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QN-302 in solid tumor (2 cohorts), sponsored by Qualigen Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 18 months and Recommended Phase 2 Dose at 24 months. Started Nov 2023; status: recruiting.
02
Drugs
QN-302
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06086522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086522.